Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.24272/j.issn.2095-8137.2021.206 http://scihub22266oqcxt.onion/10.24272/j.issn.2095-8137.2021.206 34423606!8455464!34423606     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\34423606.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Zool+Res 2021 ; 42 (5): 633-636 Nephropedia Template TP {{tp|p=34423606|t=2021. Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice |pdf=|usr=}}{{34423606}} gab.com Text Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice JO: Zool Res http://www.kidney.de/pget.php?&tw=1&pmid=34423606 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression. In the present study, we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-CoV-2. Results revealed that SARS-CoV-2 replication was delayed in hypertensive mouse lungs. In contrast, SARS-CoV-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-CoV-2-infected normotensive mice. Furthermore, antihypertensive treatment alleviated lung inflammation induced by SARS-CoV-2 replication (interleukin (IL)-1beta up-regulation and increased immune cell infiltration). No differences in lung inflammation were observed between the SARS-CoV-2-infected normotensive mice and hypertensive mice. Our findings suggest that captopril treatment may alleviate COVID-19 progression but not affect viral replication. Twit Text FOAVip Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice ????Zool Res http://www.kidney.de/pget.php?&tw=1&pmid=34423606 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34423606 #FOAvip English Wikipedia <ref>{{Cite pmid|34423606}}</ref> Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice #MMPMID34423606 Gao WC; Ma X; Wang P; He XY; Zheng YT; Liu FL; Zheng CB Zool Res 2021[Sep]; 42 (5): 633-636 PMID34423606show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression. In the present study, we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-CoV-2. Results revealed that SARS-CoV-2 replication was delayed in hypertensive mouse lungs. In contrast, SARS-CoV-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-CoV-2-infected normotensive mice. Furthermore, antihypertensive treatment alleviated lung inflammation induced by SARS-CoV-2 replication (interleukin (IL)-1beta up-regulation and increased immune cell infiltration). No differences in lung inflammation were observed between the SARS-CoV-2-infected normotensive mice and hypertensive mice. Our findings suggest that captopril treatment may alleviate COVID-19 progression but not affect viral replication. |*SARS-CoV-2[MESH] |Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH] |Animals[MESH] |Antihypertensive Agents/pharmacology/*therapeutic use[MESH] |COVID-19/*complications[MESH] |Captopril/pharmacology/*therapeutic use[MESH] |Gene Expression Regulation/drug effects[MESH] |Hypertension/*complications[MESH] |Inflammation/complications/drug therapy[MESH] |Interleukin-1beta/genetics/metabolism[MESH] |Lung Diseases/*drug therapy/etiology/virology[MESH] |Mice[MESH]Captopril alleviates lung inflammation in SARS-CoV-2-infected hyperten(epmc).pdf DeepDyve Pubget Overpricing